While CD40 targeted therapies have not yet been approved for clinical use, they represent a promising and rapidly developing area of research across a wide range of diseases.Dublin, Dec. 09, 2024 ...

In contrast, after adding 20 mg/kg of monoclonal antibody against CD40 ligand to the regimen on days 0 and 2, we observed four thromboembolic complications in nine recipients. These included two ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...